Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Theravance Biopharma Inc.

    NASDAQ: TBPH · Real-Time Price · USD
    10.71
    0.10 (0.94%)
    At close: Jun 13, 2025, 3:59 PM
    10.69
    -0.19%
    After-hours: Jun 13, 2025, 05:50 PM EDT

    Theravance Biopharma Statistics

    Share Statistics

    Theravance Biopharma has 50M shares outstanding. The number of shares has increased by 1.72% in one year.

    Shares Outstanding

    n/a
    		 50M

    Shares Change (YoY)

    n/a
    		 1.72%

    Shares Change (QoQ)

    n/a
    		 0.6%

    Owned by Institutions (%)

    n/a
    		 91.54%

    Shares Floating

    n/a
    		 45.88M

    Failed to Deliver (FTD) Shares

    n/a
    		 9

    FTD / Avg. Volume

    n/a
    		 n/a

    Short Selling Information

    The latest short interest is 3.79M, so 7.58% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 3.79M

    Short % of Shares Out

    n/a
    		 7.58%

    Short % of Float

    n/a
    		 12.28%

    Short Ratio (days to cover)

    n/a
    		 17.19

    Valuation Ratios

    The PE ratio is -8.15 and the forward PE ratio is -13.6. Theravance Biopharma's PEG ratio is -0.54.

    PE Ratio

    n/a
    		 -8.15

    Forward PE

    n/a
    		 -13.6

    PS Ratio

    n/a
    		 7.14

    Forward PS

    n/a
    		 2.2

    PB Ratio

    n/a
    		 2.62

    P/FCF Ratio

    n/a
    		 -38.73

    PEG Ratio

    n/a
    		 -0.54
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Theravance Biopharma.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 5.02, with a Debt / Equity ratio of 0.28.

    Current Ratio

    n/a
    		 5.02

    Quick Ratio

    n/a
    		 5.02

    Debt / Equity

    n/a
    		 0.28

    Debt / EBITDA

    n/a
    		 -1.3

    Debt / FCF

    n/a
    		 -4.2

    Interest Coverage

    n/a
    		 -18.44

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $663,721.65

    Profits Per Employee

    n/a
    		 $-581,628.87

    Employee Count

    n/a
    		 97

    Asset Turnover

    n/a
    		 0.18

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 11.8M

    Effective Tax Rate

    n/a
    		 -26.46%

    Stock Price Statistics

    The stock price has increased by 26.3% in the last 52 weeks. The beta is -0.08, so Theravance Biopharma's price volatility has been lower than the market average.

    Beta

    n/a
    		 -0.08

    52-Week Price Change

    n/a
    		 26.3%

    50-Day Moving Average

    n/a
    		 9.55

    200-Day Moving Average

    n/a
    		 9.15

    Relative Strength Index (RSI)

    n/a
    		 59.12

    Average Volume (20 Days)

    n/a
    		 278,598

    Income Statement

    In the last 12 months, Theravance Biopharma had revenue of 64.38M and earned -56.42M in profits. Earnings per share was -1.15.

    Revenue

    n/a
    		 64.38M

    Gross Profit

    n/a
    		 64.38M

    Operating Income

    n/a
    		 -46.95M

    Net Income

    n/a
    		 -56.42M

    EBITDA

    n/a
    		 -38.45M

    EBIT

    n/a
    		 -42.07M

    Earnings Per Share (EPS)

    n/a
    		 -1.15
    Full Income Statement

    Balance Sheet

    The company has 37.8M in cash and 49.82M in debt, giving a net cash position of -12.02M.

    Cash & Cash Equivalents

    n/a
    		 37.8M

    Total Debt

    n/a
    		 49.82M

    Net Cash

    n/a
    		 -12.02M

    Retained Earnings

    n/a
    		 -965.52M

    Total Assets

    n/a
    		 343.58M

    Working Capital

    n/a
    		 118.76M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -11.54M and capital expenditures -332K, giving a free cash flow of -11.87M.

    Operating Cash Flow

    n/a
    		 -11.54M

    Capital Expenditures

    n/a
    		 -332K

    Free Cash Flow

    n/a
    		 -11.87M

    FCF Per Share

    n/a
    		 -0.24
    Full Cash Flow Statement

    Margins

    Gross margin is 90.66%, with operating and profit margins of -72.92% and -87.63%.

    Gross Margin

    n/a
    		 90.66%

    Operating Margin

    n/a
    		 -72.92%

    Pretax Margin

    n/a
    		 -69.3%

    Profit Margin

    n/a
    		 -87.63%

    EBITDA Margin

    n/a
    		 -72.92%

    EBIT Margin

    n/a
    		 -72.92%

    FCF Margin

    n/a
    		 -18.43%

    Dividends & Yields

    TBPH does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for TBPH is $10, which is -6.6% lower than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $10

    Price Target Difference

    n/a
    		 -6.6%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 3
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -2.26

    Piotroski F-Score

    n/a
    		 4

    Add to Watchlist